Trial Profile

Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Dec 2017 The U.S. Food and Drug Administration has approved Admelog (insulin lispro injection), indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus, as reported in a US FDA media release.
13 Jun 2017 Results of SORELLA 1 and SORELLA 2 trials presented at the 77th Annual Scientific Sessions of the American Diabetes Association
13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com